FDA expands Vyjuvek use to newborn DEB patients with more flexible wound care options. Real-world data confirms Vyjuvek's safety and effectiveness across all age groups. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first → The U.S.

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Krystal Biotech KRYS has outperformed the market over the past 5 years by 13.77% on an annualized basis producing an average annual return of 27.56%. Currently, Krystal Biotech has a market capitalization of $4.28 billion.

Krystal Biotech KRYS has outperformed the market over the past 5 years by 12.38% on an annualized basis producing an average annual return of 26.0%. Currently, Krystal Biotech has a market capitalization of $4.32 billion.

Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.